Willingdon Wealth Management boosted its holdings in Celgene Co. (NASDAQ:CELG) by 77.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,827 shares of the biopharmaceutical company’s stock after buying an additional 14,757 shares during the period. Celgene makes up about 1.2% of Willingdon Wealth Management’s investment portfolio, making the stock its 25th largest position. Willingdon Wealth Management’s holdings in Celgene were worth $3,530,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Fort Pitt Capital Group LLC increased its position in shares of Celgene by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after purchasing an additional 11 shares during the period. Linscomb & Williams Inc. boosted its stake in Celgene by 1.0% in the 2nd quarter. Linscomb & Williams Inc. now owns 3,813 shares of the biopharmaceutical company’s stock valued at $495,000 after buying an additional 36 shares in the last quarter. RNC Capital Management LLC boosted its stake in Celgene by 0.9% in the 2nd quarter. RNC Capital Management LLC now owns 5,270 shares of the biopharmaceutical company’s stock valued at $684,000 after buying an additional 45 shares in the last quarter. Marietta Wealth Management LLC boosted its stake in Celgene by 1.9% in the 2nd quarter. Marietta Wealth Management LLC now owns 4,141 shares of the biopharmaceutical company’s stock valued at $538,000 after buying an additional 78 shares in the last quarter. Finally, Bank Hapoalim BM boosted its stake in Celgene by 4.9% in the 2nd quarter. Bank Hapoalim BM now owns 1,812 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 85 shares in the last quarter. 78.60% of the stock is currently owned by institutional investors.
Several analysts recently commented on the company. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price target on the stock in a research note on Thursday, January 25th. Mizuho set a $128.00 price target on Celgene and gave the company a “buy” rating in a research note on Tuesday, December 26th. BTIG Research reaffirmed a “hold” rating on shares of Celgene in a research note on Tuesday, January 23rd. BidaskClub raised Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, Citigroup reaffirmed a “hold” rating on shares of Celgene in a research note on Friday, December 22nd. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. Celgene has an average rating of “Buy” and a consensus price target of $127.78.
Shares of Celgene Co. (CELG) opened at $86.91 on Friday. The firm has a market capitalization of $66,424.63, a price-to-earnings ratio of 12.87, a PEG ratio of 0.62 and a beta of 1.58. Celgene Co. has a 52-week low of $86.55 and a 52-week high of $147.17. The company has a debt-to-equity ratio of 2.29, a quick ratio of 4.80 and a current ratio of 4.99.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.78 by $0.09. The company had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm’s quarterly revenue was up 16.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.61 earnings per share. research analysts forecast that Celgene Co. will post 7.66 EPS for the current year.
Celgene announced that its board has approved a share repurchase plan on Wednesday, February 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.
In related news, Director Ernest Mario sold 13,370 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $94.49, for a total value of $1,263,331.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $95.99, for a total value of $887,907.50. Following the completion of the sale, the director now owns 94,801 shares of the company’s stock, valued at approximately $9,099,947.99. The disclosure for this sale can be found here. Insiders sold 41,120 shares of company stock valued at $3,879,509 in the last quarter. 0.95% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Celgene Co. (CELG) Holdings Lifted by Willingdon Wealth Management” was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://transcriptdaily.com/2018/03/23/celgene-co-celg-holdings-lifted-by-willingdon-wealth-management.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.